Evidence map›Paper›PMID 16603615›Full record

ArticleClinical and vaccine immunology : CVI2006

High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen.

Trang V Nguyen, Lijuan Yuan, Marli S P Azevedo, Kwang-il Jeong, Ana M Gonzalez, Cristiana Iosef, Karin Lovgren-Bengtsson, Bror Morein, Peggy Lewis, Linda J Saif

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 51 citations in OpenAlex.

  1. Breast Milk-Derived Antibodies Impair Vaccine Immunity in Suckling Mice.Journal of immunology (Baltimore, Md. : 1950) · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Why does the world need another rotavirus vaccine?Therapeutics and clinical risk management · 2008
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Trang V NguyenFood Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, 1680 Madison Avenue, Wooster, OH 44691-4096, USA.
Lijuan Yuan
Marli S P Azevedo
Kwang-il Jeong
Ana M Gonzalez
Cristiana Iosef
Karin Lovgren-Bengtsson
Bror Morein
Peggy Lewis
Linda J Saif
The Ohio State University · USSwedish University of Agricultural Sciences · SEWestern University · CA

Funding

ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINESR01AI033561 · NIAID · OHIO STATE UNIVERSITY · PI SAIF, LINDA J. · 1992 to 2006
$945k
IMMUNE RESPONSE TO ROTAVIRUS--MATERNAL ANTIBODIESR01AI037111 · NIAID · OHIO STATE UNIVERSITY · PI SAIF, LINDA J. · 1994 to 2003
$936k
NIAID NIH HHS R01 AI033561NIAID NIH HHS R01 AI037111NIAID NIH HHS R01AI33561NIAID NIH HHS R01AI37111
6 · The paper itself

Abstract

We investigated maternal antibody (MatAb) effects on protection and immune responses to rotavirus vaccines. Gnotobiotic pigs were injected intraperitoneally at birth with pooled serum from sows hyperimmunized with human rotavirus (HRV); control pigs received no sow serum. Pigs with or without MatAbs received either sequential attenuated HRV (AttHRV) oral priming and intranasal boosting with VP2/VP6 virus-like particle (VLP)-immunostimulating complex (ISCOM) (AttHRV/VLP) or intranasal VLP-ISCOM prime/boost (VLP) vaccines at 3 to 5 days of age. Subsets of pigs were challenged at 28 or 42 days postinoculation with virulent Wa HRV to assess protection. Isotype-specific antibody-secreting cell (ASC) responses to HRV were quantitated by enzyme-linked immunospot assay to measure effector and memory B-cell responses in intestinal and systemic lymphoid tissues pre- and/or postchallenge. Protection rates against HRV challenge (contributed by active immunity and passive circulating MatAbs) were consistently (but not significantly) lower in the MatAb-AttHRV/VLP groups than in the corresponding groups without MatAbs. Intestinal B-cell responses in the MatAb-AttHRV/VLP group were most suppressed with significantly reduced or no intestinal immunoglobulin A (IgA) and IgG effector and memory B-cell responses or antibody titers pre- and postchallenge. This suppression was not alleviated but was enhanced after extending vaccination/challenge from 28 to 42 days. In pigs vaccinated with nonreplicating VLP alone that failed to induce protection, MatAb effects differed, with intestinal and systemic IgG ASCs and prechallenge memory B cells suppressed but the low intestinal IgA and IgM ASC responses unaffected. Thus, we demonstrate that MatAbs differentially affect both replicating and nonreplicating HRV vaccines and suggest mechanisms of MatAb interference. This information should facilitate vaccine design to overcome MatAb suppression.

Indexed as

Immunity, Maternally-AcquiredImmunization, SecondaryImmunologic MemoryAnimalsAnimals, NewbornAntibodies, ViralB-LymphocytesDiarrheaFemaleHumansInfantInfant, NewbornInjections, IntraperitonealISCOMsRotavirusRotavirus VaccinesAntibodies, ViralISCOMsRotavirus VaccinesVaccines, Attenuated

Identifiers

PMID16603615
PMCPMC1459641
OpenAlexW2106898979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.